Clinical Trial Update: Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease [Phase 3]

View source ↗

Summary

A Phase 3 study of brimonidine tartrate nanoemulsion eye drops for ocular graft-versus-host disease has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Ocular Surface Disease

Drugs mentioned

• Brimonidine tartrate nanoemulsion eye drops (brimonidine tartrate)

Snippet

Sponsor: Ocugen | Conditions: Graft Versus Host Disease, Ocular Surface Disease | Phase 3 | Status: TERMINATED | Results posted: 2022-07-06